MCID: ADN001
MIFTS: 44

Adenosine Deaminase Deficiency malady

Categories: Genetic diseases, Rare diseases, Immune diseases, Metabolic diseases, Blood diseases

Aliases & Classifications for Adenosine Deaminase Deficiency

About this section
Sources:
45NIH Rare Diseases, 23Genetics Home Reference, 10Disease Ontology, 21GeneReviews, 22GeneTests, 47Novoseek, 12DISEASES, 65UMLS, 11diseasecard, 51Orphanet, 27ICD10, 42NCIt, 59SNOMED-CT, 28ICD10 via Orphanet, 37MESH via Orphanet, 66UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Adenosine Deaminase Deficiency:

Name: Adenosine Deaminase Deficiency 10 21 45 22 23 47 12 65
Ada Deficiency 21 45 22 23 51
Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency 45 51 65
Ada-Scid 21 45 23
Severe Combined Immunodeficiency, Autosomal Recessive, T Cell-Negative, B Cell-Negative, Nk Cell-Negative, Due to Adenosine Deaminase Deficiency 45 23
Adenosine Deaminase Deficient Severe Combined Immunodeficiency 45 23
Severe Combined Immunodeficiency Due to Ada Deficiency 45 23
 
Scid Due to Ada Deficiency 45 23
Adenosine Deaminase-Deficient Severe Combined Immunodeficiency Disease 22
Ada-Deficient Severe Combined Immunodeficiency Disease 22
Scid Due to Adenosine Deaminase Deficiency 51
Partial Adenosine Deaminase Deficiency 65
Adenosine Deaminase 11
Ada 10

Characteristics:

Orphanet epidemiological data:

51
ada deficiency:
Inheritance: Autosomal recessive; Prevalence: 1-9/1000000 (Europe); Age of onset: Infancy,Neonatal; Age of death: early childhood

Classifications:



External Ids:

Disease Ontology10 DOID:5810
ICD1027 D81.3
NCIt42 C3962
Orphanet51 277
ICD10 via Orphanet28 D81.3
MESH via Orphanet37 C531816
UMLS via Orphanet66 C0392607
UMLS65 C0268124, C1863239, C0392607

Summaries for Adenosine Deaminase Deficiency

About this section
NIH Rare Diseases:45 Adenosine deaminase deficiency (ada) is an inherited condition that affects the immune system and typically leads to severe combined immunodeficiency (scid). people with scid have a reduced or absent immune response which leaves them vulnerable to frequent bacterial, viral, and fungal infections. most people affected by ada develop symptoms of the condition before 6 months of age. however, approximately 10-15% of affected people have a "delayed" onset of symptoms; diagnosis of these cases, which are often less severe, typically takes place later in childhood (often between age 1 and 10) or even into adulthood. signs and symptoms of ada include pneumonia, chronic diarrhea, widespread skin rashes, slowed growth and/or developmental delay. ada is caused by changes (mutations) in the ada gene and is inherited in an autosomal recessive manner. the most effective treatment is transplantation of blood-forming stem cells from the bone marrow of a healthy person.[8061 last updated: 1/4/2015

MalaCards based summary: Adenosine Deaminase Deficiency, also known as ada deficiency, is related to adenosine deaminase 2 deficiency and delayed-/late-onset adenosine deaminase deficiency. An important gene associated with Adenosine Deaminase Deficiency is ADA (Adenosine Deaminase), and among its related pathways are Primary immunodeficiency and purine nucleotides de novo biosynthesis. Affiliated tissues include bone, t cells and skin, and related mouse phenotypes are respiratory system and hematopoietic system.

Disease Ontology:10 A severe combined immunodeficiency that is caused by a defective enzyme, adenosine deaminase (ADA), necessary for the breakdown of purines. Lack of ADA causes accumulation of dATP.

Genetics Home Reference:23 Adenosine deaminase (ADA) deficiency is an inherited disorder that damages the immune system and causes severe combined immunodeficiency (SCID). People with SCID lack virtually all immune protection from bacteria, viruses, and fungi. They are prone to repeated and persistent infections that can be very serious or life-threatening. These infections are often caused by "opportunistic" organisms that ordinarily do not cause illness in people with a normal immune system.

Wikipedia:68 Adenosine deaminase deficiency, also called ADA deficiency or ADA-SCID, is an autosomal... more...

GeneReviews summary for NBK1483

Related Diseases for Adenosine Deaminase Deficiency

About this section

Graphical network of the top 20 diseases related to Adenosine Deaminase Deficiency:



Diseases related to adenosine deaminase deficiency

Symptoms for Adenosine Deaminase Deficiency

About this section

Drugs & Therapeutics for Adenosine Deaminase Deficiency

About this section

Drugs for Adenosine Deaminase Deficiency (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 10)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Adenosineapproved, investigationalPhase 3, Phase 1, Phase 236358-61-760961
Synonyms:
(2R,3R,4S,5R)-2-(6-Aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
1-(6-Amino-9H-purin-9-yl)-1-deoxy-beta-D-Ribofuranose
1-(6-Amino-9H-purin-9-yl)-1-deoxy-beta-delta-Ribofuranose
1odi
2fqy
2gl0
30143-02-3
4-Aminopyrazolo[3,4-d]pyrimidine ribonucleoside
46946-45-6
46969-16-8
58-61-7
6-Amino-9-.beta.-ribofuranosyl-9H-purine
6-Amino-9-beta-D-ribofuranosyl-9H-purine
6-Amino-9beta-D-ribofuranosyl-9H-purine
6-Amino-9beta-delta-ribofuranosyl-9H-purine
9-(beta-D-Arabinofuranosyl)adenine
9-beta-D-Arabinofuranosyladenine
9-beta-D-Ribofuranosidoadenine
9-beta-D-Ribofuranosyl-9H-purin-6-amine
9-beta-D-Ribofuranosyladenine
9-beta-delta-Arabinofuranosyladenine
9-beta-delta-Ribofuranosidoadenine
9-beta-delta-Ribofuranosyl-9H-purin-6-amine
9-beta-delta-Ribofuranosyladenine
9beta-D-Ribofuranosyladenine
9beta-D-ribofuranosyl-9H-Purin-6-amine
9beta-delta-Ribofuranosyladenine
9beta-delta-ribofuranosyl-9H-Purin-6-amine
A0152
A4036_SIGMA
A9251_SIGMA
AC1L1U8O
AC1Q1ID3
AC1Q52XU
ADN
AI3-52413
Ade-Rib
Ade-rib
Adenin riboside
Adenine 9-beta-D-arabinofuranoside
Adenine deoxyribonucleoside
Adenine nucleoside
Adenine riboside
Adenine-9-beta-D-ribofuranoside
Adenine-9beta-D-Ribofuranoside
Adenine-9beta-delta-Ribofuranoside
Adenocard
Adenocard (TN)
Adenocard, Adenosine
Adenocor
Adenoscan
Adenoscan (TN)
Adenosin
Adenosin [German]
Adenosina
Adenosine
Adenosine (JAN/USP)
Adenosine [USAN:BAN]
Adenosine, homopolymer
Adenosinum
Adensoine
Adenyldeoxyriboside
Ado
Adénosine
BB_NC-0565
BSPBio_001796
Bio1_000437
 
Bio1_000926
Bio1_001415
Boniton
C00212
CCRIS 2557
CHEBI:16335
CHEMBL477
CID60961
Caswell No. 010B
D000241
D00045
DB00640
Deoxyadenosine
Desoxyadenosine
EA6C60C2-6AFB-4264-A2F0-541373DB950E
EINECS 200-389-9
FT-0082881
HMS1920A13
HMS2091G13
KBio3_001296
LS-15085
MEDR-640
MLS000069638
MLS002153227
MolPort-001-838-229
Myocol
NCGC00023673-03
NCGC00023673-04
NCGC00023673-05
NCGC00023673-06
NCGC00023673-07
NSC 627048
NSC 7652
NSC627048
NSC7652
Nucleocardyl
Pallacor
Polyadenosine
Polyriboadenosine
S1647_Selleck
SDCCGMLS-0003108.P003
SMR000058216
SPBio_001194
SPECTRUM1500107
SR 96225
SR-96225
SUN-Y4001
Sandesin
Spectrum2_001257
Spectrum3_000288
TL8003749
UNII-K72T3FS567
USAF CB-10
V0098
Vidarabine
ZINC02169830
adenine-D-ribose
adenosine
b-D-Adenosine
beta-Adenosine
beta-D-Adenosine
beta-D-Ribofuranoside, adenine-9
beta-delta-Adenosine
bmse000061
nchembio.143-comp9
nchembio.186-comp109
nchembio.2007.56-comp13
nchembio.64-comp4
nchembio706-5
2
Busulfanapproved, investigationalPhase 1, Phase 250655-98-12478
Synonyms:
1, 4-Dimethanesulfonoxybutane
1, 4-Dimethylsulfonoxybutane
1, {4-Bis[methanesulfonoxy]butane}
1,4-BUTANEDIOL DIMETHANESULFONATE
1,4-Bis(methanesulfonoxy)butane
1,4-Bis(methanesulfonyloxy)butane
1,4-Bis[methanesulfonoxy]butane
1,4-Butanedi yl dimethanesulfonate
1,4-Butanediol dimethanesulfonate
1,4-Butanediol dimethanesulphonate
1,4-Butanediol dimethylsulfonate
1,4-Butanediol, dimethanesulfonate
1,4-Butanediol, dimethanesulphonate
1,4-Butanediyl dimethanesulfonate
1,4-Di(methylsulfonoxy)butane
1,4-Dimesyloxybutane
1,4-Dimethane sulfonyl oxybutane
1,4-Dimethanesulfonoxybutane
1,4-Dimethanesulfonoxylbutane
1,4-Dimethanesulfonyloxybutane
1,4-Dimethanesulphonyloxybutane
1,4-Dimethylsulfonoxybutane
1,4-Dimethylsulfonyloxybutane
2041 C. B
2041 C. B.
2041 C.B
2041 C.B.
4-((Methylsulfonyl)oxy)butyl methanesulfonate
4-methylsulfonyloxybutyl methanesulfonate
55-98-1
AC-198
AC1L1DRQ
AC1Q4GRQ
AI3-25012
AKOS003614975
AN 33501
Ambap55-98-1
B1022
B2635_FLUKA
B2635_SIGMA
BRN 1791786
BSPBio_001920
BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE)
Bisulfex
Busilvex
Busulfan
Busulfan (JP15/USP/INN)
Busulfan GlaxoSmithKline Brand
Busulfan Orphan Brand
Busulfan Wellcome
Busulfan Wellcome Brand
Busulfan [INN:JAN]
Busulfano
Busulfano [INN-Spanish]
Busulfanum
Busulfanum [INN-Latin]
Busulfex
Busulphan
Busulphane
Butanedioldimethanesulfonate
Buzulfan
C.B. 2041
C6H14O6S2
CB 2041
CCRIS 418
CHEBI:28901
CHEMBL820
CID2478
CPD000058613
Citosulfan
D002066
D00248
DB01008
DivK1c_000847
EINECS 200-250-2
FT-0083567
G.T. 41
GT 2041
GT 41
Glaxo Wellcome Brand of Busulfan
GlaxoSmithKline Brand of Busulfan
Glyzophrol
HMS1920I07
HMS2091O09
HMS502K09
 
HSDB 7605
I09-1371
IDI1_000847
InChI=1/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3
KBio1_000847
KBio2_000512
KBio2_003080
KBio2_005648
KBio3_001420
KBioGR_000698
KBioSS_000512
LS-1358
Leucosulfan
MLS001076666
MYLERAN (TN)
Mablin
Methanesulfonic
Methanesulfonic acid, tetram ethylene ester
Methanesulfonic acid, tetramethylene ester
Mielevcin
Mielosan
Mielucin
Milecitan
Mileran
Misulban
Mitosan
Mitostan
MolPort-001-783-406
Myeleukon
Myeloleukon
Myelosan
Myelosanum
Mylecytan
Myleran
Myleran Tablets
Myleran tablets
Myleran, Busulfex, Busulfan
Mylerlan
NCGC00090905-01
NCGC00090905-02
NCGC00090905-03
NCGC00090905-04
NCGC00090905-05
NCGC00090905-06
NCGC00090905-07
NCI-C01592
NCI60_041640
NCIMech_000192
NINDS_000847
NSC 750
NSC-750
NSC-750sulphabutin
NSC750
Orphan Brand of Busulfan
Prestwick_989
S1692_Selleck
SAM002554887
SMR000058613
SPBio_000253
SPECTRUM1500152
ST50825921
Spectrum2_000067
Spectrum3_000320
Spectrum4_000259
Spectrum5_000928
Spectrum_000092
Sulfabutin
Sulfabutin (VAN)
Sulphabutin
Tetramethylene Dimethane Sulfonate
Tetramethylene bis(methanesulfonate)
Tetramethylene bis[methanesulfonate]
Tetramethylene dimethane sulfonate
Tetramethylene {bis[methanesulfonate]}
Tetramethylenester Kyseliny Methansulfonove
Tetramethylenester kyseliny methansulfonove
Tetramethylenester kyseliny methansulfonove [Czech]
UNII-G1LN9045DK
WLN: WS1&O4OSW1
Wellcome Brand of Busulfan
Wellcome, Busulfan
X 149
acid, tetramethylene ester
alkylating agent: crosslinks guanine residues
busulfan
butane-1,4-diyl dimethanesulfonate
n-Butane-1,3-di(methylsulfonate)
3AnestheticsPhase 1, Phase 27385
4
ZidovudineapprovedPhase 149130516-87-135370
Synonyms:
-Azido-3&prime
-deoxythymidine
1-(3-Azido-2,3-dideoxy-beta-D-ribofuranosyl)thymine
3&prime
3' Azido 2',3' Dideoxythymidine
3' Azido 3' deoxythymidine
3'-Azido-2',3'-Dideoxythymidine
3'-Azido-3'-deoxythymidine
3'-Azido-3'-deoxythymidine & Concanavalin A
3'-Azido-3'-deoxythymidine & Erythropoietin
3'-Azido-3'-deoxythymidine & Heteropolyoxotungstate PM-19
3'-Azido-3'-deoxythymidine & Interleukin-1
3'-Azido-3'-deoxythymidine & Interleukin-2
3'-Azido-3'-deoxythymidine & Interleukin-6
3'-Azido-3'-deoxythymidine & Lithium & Erythropoietin
3'-Azido-3'-deoxythymidine & Lithium & Interleukin-1
3'-Azido-3'-deoxythymidine & Lithium & Interleukin-6
3'-Azido-3'-deoxythymidine & Lymphoblastoid Interferon
3'-Azido-3'-deoxythymidine & Sho-Saiko-To
3'-Azido-3'-deoxythymidine (AIDS)
3'-Azido-3'deoxythymidine & Interferon .alpha.
3'-Azidothymidine
3'-Deoxy-3'-azidothymidine
3'-azido-3'-deoxythymidine, AZT
3-Azido-3-deoxythymidine
30516-87-1
399024-19-2
A2169_SIGMA
AC1L1TKL
AC1Q2OEK
AZT
AZT & CD4(178)-PE 40
AZT & Colony-stimulating factor 2
AZT & Concanavalin A (ConA)
AZT & EPO
AZT & GM-CSF
AZT & HPA
AZT & IFN.alpha.
AZT & IL-1
AZT & IL-2
AZT & IL-6
AZT & Interferon-.alpha.-2
AZT & Li & EPO
AZT & Li & GM-CSF
AZT & Li & IL-1
AZT & Li & IL-6
AZT & Lymphoblastoid Interferon
AZT & NP (from PHCA or HSA)
AZT & PM-19
AZT & SST
AZT & rIFN.alpha.2
AZT & rsCD4 & rIFN.alpha.A
AZT & rsT4
AZT & sCD4
AZT & srCD4
AZT (Antiviral)
AZT Antiviral
AZT TRANSPLACENTAL CARCINOGENESIS STUDY
AZT+PRO 140
AZT, Antiviral
Antiviral AZT
Apo-Zidovudine
Azidothymidine
Aztec
BB_NC-1012
BPBio1_000403
BRD-K72903603-001-04-6
BSPBio_000365
BSPBio_003153
BW A509U
BW-A 509U
BW-A-509U
BW-A509U
BWA 509U
BWA-509U
BWA509U
C07210
CCRIS 105
CHEBI:10110
CHEBI:127307
CHEMBL129
CID35370
CPD000058351
 
Compound S
Cpd S
D00413
D015215
DB00495
DRG-0004
DS-4152 & AZT
DivK1c_000524
HMS1921J20
HMS2090G11
HMS2092D06
HMS501K06
HSDB 6515
IDI1_000524
Interferon AD + 3'-azido-3'-deoxythymidine
Intron A & AZT
K7 [P Ti2 W10 O40]
KBio1_000524
KBio2_001828
KBio2_004396
KBio2_006964
KBio3_002653
KBioGR_000703
KBioSS_001828
LS-1159
Liposomal AZT-SN-1
Liposomal AZT-SN-3
MLS000028548
MLS001055351
MLS001076358
MLS002153202
MLS002222249
Met-SDF-1.beta. & AZT
Met-SDF-1.beta. & Zidovudine
MolPort-002-507-286
NCGC00023945-03
NCGC00023945-04
NCGC00023945-05
NCGC00023945-08
NCGC00178237-01
NCGC00178237-02
NINDS_000524
NSC 602670
Novo-Azt
PC-SOD+AZT
Prestwick3_000333
Propolis+AZT
Racemic Liposomal AZT
Retrovir
Retrovir (TN)
Retrovir(TM)
SAM002548971
SMR000058351
SN-1-dipalmitoylglycerophospho-AZT (in a lipid vesicle)
SN-3-dipalmitoylglycerophospho-AZT (in a lipid vesicle)
SPBio_000834
SPECTRUM1502109
STK801891
Spectrum2_000927
Spectrum3_001507
Spectrum4_000332
Spectrum5_001101
Spectrum_001348
UNII-4B9XT59T7S
ZDV
ZIDOVUDINE [AZT]
ZINC03779042
ZVD
Zidovudin
Zidovudina
Zidovudina [Spanish]
Zidovudine
Zidovudine (JAN/USP/INN)
Zidovudine EP III
Zidovudine [USAN:INN:BAN:JAN]
Zidovudine+PRO 140
Zidovudinum
Zidovudinum [Latin]
antiviral
azidodeoxythymidine
rIFN-beta seron & AZT
racemic-dipalmitoylglycerophospho-AZT (in a lipid vesicle)
zidovudin
zidovudine
5Purinergic P1 Receptor Agonists131
6Vasodilator Agents2926
7Peripheral Nervous System Agents18510
8Analgesics9358
9Anti-Arrhythmia Agents2371
10Neurotransmitter Agents14795

Interventional clinical trials:

(show all 18)
idNameStatusNCT IDPhase
1EZN-2279 in Patients With ADA-SCIDRecruitingNCT01420627Phase 3
2Gene Therapy ADA DeficiencyCompletedNCT01279720Phase 1, Phase 2
3Gene Therapy for ADA-SCIDCompletedNCT00599781Phase 1, Phase 2
4Lentiviral Gene Therapy for Adenosine Deaminase (ADA) DeficiencyRecruitingNCT01380990Phase 1, Phase 2
5Autologous Transplant of EFS-ADA Modified Bone Marrow Cells for ADA-Deficient Severe Combined Immunodeficiency (SCID)RecruitingNCT01852071Phase 1, Phase 2
6MND-ADA Transduction of CD34+ Cells From Children With ADA-SCIDActive, not recruitingNCT00794508Phase 2
7ADA Gene Transfer Into Hematopoietic Stem/Progenitor Cells for the Treatment of ADA-SCIDActive, not recruitingNCT00598481Phase 2
8Treatment of SCID Due to ADA Deficiency With Autologous Transplantation of Cord Blood or Hematopoietic CD 34+ Cells After Addition of a Normal Human ADA cDNA by the EFS-ADA Lentiviral VectorCompletedNCT02022696Phase 1
9Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) DeficiencyCompletedNCT00018018Phase 1
10Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency: A Natural History StudyCompletedNCT00001255
11Participation in a Research Registry for Immune DisordersRecruitingNCT01953016
12Natural History Study of SCID DisordersRecruitingNCT01186913
13Patients Treated for SCID (1968-2010)RecruitingNCT01346150
14The Role of Bacteria and Genetic Variations in Cystic FibrosisRecruitingNCT00043225
15Idiopathic CD4 LymphocytopeniaRecruitingNCT02113930
16Molecular and Clinical Studies of Primary Immunodeficiency DiseasesEnrolling by invitationNCT00006319
17Emergency Use of Adoptive Immunotherapy With CMV-Specific T Cells After Donor Bone Marrow Transplant of an Infant With Immunodeficiency Syndrome and CMV InfectionNo longer availableNCT00547235
18Quality of Life and Neuropsychiatric Sequelae in Patients Treated With Gene Therapy for ADA-SCID and in Their ParentsWithdrawnNCT01182857

Search NIH Clinical Center for Adenosine Deaminase Deficiency

Genetic Tests for Adenosine Deaminase Deficiency

About this section

Genetic tests related to Adenosine Deaminase Deficiency:

id Genetic test Affiliating Genes
1 Adenosine Deaminase Deficiency22 ADA
2 Adenosine Deaminase-Deficient Severe Combined Immunodeficiency Disease (scid)22

Anatomical Context for Adenosine Deaminase Deficiency

About this section

MalaCards organs/tissues related to Adenosine Deaminase Deficiency:

33
Bone, T cells, Skin, B cells, Nk cells, Bone marrow, Neutrophil

Animal Models for Adenosine Deaminase Deficiency or affiliated genes

About this section

MGI Mouse Phenotypes related to Adenosine Deaminase Deficiency:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053887.8ADA, ADK, GBA, IL2RG, ITPA
2MP:00053977.7ADA, AHCY, GBA, IL2RG, ITPA
3MP:00107687.1ADA, ADK, AHCY, GBA, IL2RG, ITPA

Publications for Adenosine Deaminase Deficiency

About this section

Articles related to Adenosine Deaminase Deficiency:

(show top 50)    (show all 264)
idTitleAuthorsYear
1
Right Aortic Arch with Aplasia of the Left Brachiocephalic Trunk Presented as Systolic Blood Pressure Difference Between Upper Extremities. (26966474)
2016
2
Regional variations in home canning practices and the risk of foodborne botulism in the republic of georgia, 2003. (25836400)
2015
3
Lentivirus-mediated siRNA targeting sae1 induces cell cycle arrest and apop- tosis in colon cancer cell RKO]. (25842831)
2014
4
Japanese encephalitis virus isolation from mosquitoes during an outbreak in 2011 in Alappuzha district, Kerala. (24220084)
2013
5
Prevalence of Obstructive Sleep Apnea After Orticochea Pharyngoplasty for Velopharyngeal Insufficiency Management. (23952561)
2013
6
Center of Cleft Lip-cleft Palate and Craniofacial Deformities, Khon Kaen University in association with "Tawanchai Project" and Faculty Of Medicine, Khon Kaen University. (24386735)
2013
7
Hypercalcemia in disseminated coccidioidomycosis: expression of parathyroid hormone-related peptide is characteristic of granulomatous inflammation. (22670039)
2012
8
Pituitary cyclic Cushing's syndrome concomitant with solitary cryptococcal pneumonia confused with ectopic ACTH-producing tumor. (22576386)
2012
9
Genome-wide CpG island profiling of intraductal papillary mucinous neoplasms of the pancreas. (22173550)
2012
10
Molecular epidemiology of chronic hepatitis B virus infection in Greece. (21181918)
2011
11
Differential role of DNA-PKcs phosphorylations and kinase activity in radiosensitivity and chromosomal instability. (21175350)
2011
12
A large deletion in the succinate dehydrogenase B gene (SDHB) in a Japanese patient with abdominal paraganglioma and concomitant metastasis. (20379037)
2010
13
Relationship between endolymphatic hydrops and vestibular-evoked myogenic potential. (20105111)
2010
14
Raman profiles of the stratum corneum define 3 filaggrin genotype-determined atopic dermatitis endophenotypes. (20621340)
2010
15
Selective targeting of radiation-resistant tumor-initiating cells. (20133717)
2010
16
Peroxisome proliferator-activated receptor-gamma and retinoid X receptor agonists synergistically suppress proliferation of immortalized endometrial stromal cells. (18571164)
2009
17
Dual-energy CT angiography in peripheral arterial occlusive disease. (19130122)
2009
18
The effect of N-acetylcysteine on proteinuria and markers of tubular injury in non-diabetic patients with chronic kidney disease. A placebo-controlled, randomized, open, cross-over study. (19092257)
2008
19
Acute coronary syndrome associated with Churg-Strauss syndrome. (18078031)
2007
20
EV71 induces VCAM-1 expression via PDGF receptor, PI3-K/Akt, p38 MAPK, JNK and NF-kappaB in vascular smooth muscle cells. (17669626)
2007
21
Is conservative treatment really effective for Legg-CalvAc-Perthes disease? A critical review of the literature. (18402012)
2007
22
AMP-activated protein kinase signaling in metabolic regulation. (16823475)
2006
23
Enrichment of genes in the aortic intima that are associated with stratified epithelium: implications of underlying biomechanical and barrier properties of the arterial intima. (15867175)
2005
24
Sustained osteomalacia of long bones despite major improvement in other hypophosphatasia-related mineral deficits in tissue nonspecific alkaline phosphatase/nucleotide pyrophosphatase phosphodiesterase 1 double-deficient mice. (15920156)
2005
25
Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis. (15572720)
2004
26
Alleles of a reelin CGG repeat do not convey liability to autism in a sample from the CPEA network. (15048647)
2004
27
A form of albinism in cattle is caused by a tyrosinase frameshift mutation. (14727143)
2004
28
A proximal gene promoter region for the beta-amyloid precursor protein provides a link between development, apoptosis, and Alzheimer's disease. (15033805)
2003
29
Androgenic regulation of oxidative stress in the rat prostate: involvement of NAD(P)H oxidases and antioxidant defense machinery during prostatic involution and regrowth. (14633623)
2003
30
Phenotypical and functional characterization of clinical grade dendritic cells. (12218781)
2002
31
Pseudomonas aeruginosa activates human mast cells to induce neutrophil transendothelial migration via mast cell-derived IL-1 alpha and beta. (12370389)
2002
32
Positive malignant hyperthermia susceptibility in vitro test in a patient with mitochondrial myopathy and myoadenylate deaminase deficiency. (12459698)
2002
33
The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand. (11103780)
2000
34
A new method of measuring C-reactive protein, with a low limit of detection, suitable for risk assessment of coronary heart disease. (10389199)
1999
35
Nitric oxide in sepsis and endotoxaemia. (9511084)
1998
36
Infantile hypertrophic pyloric stenosis presenting as pseudo-Bartter's syndrome and seizures: report of one case. (9684526)
1998
37
Neurobiology of lithium: an update. (9674936)
1998
38
Mosaicism due to a somatic mutation of the androgen receptor gene determines phenotype in androgen insensitivity syndrome. (9360511)
1997
39
Clinical features and molecular analysis of a family with multiple colon tumours and reduced plasminogen activator activity. (9112141)
1997
40
MR of the caudal regression syndrome: embryologic implications. (8073969)
1994
41
Phaeochromocytoma and familial tumour syndromes. (7913426)
1994
42
Lack of accuracy of plasma alpha-amino nitrogen profiles as an indicator of exocrine pancreatic function both after continuous and bolus stimulation of the pancreas with secretin and cholecystokinin-pancreozymin. (7871858)
1994
43
Pancreatic insulinoma, adenomatosis of the Wirsung's duct and chronic pancreatitis. Apropos of a case]. (8135587)
1993
44
Human melanotransferrin (p97) has only one functional iron-binding site. (1544447)
1992
45
Proliferative effect of dexamethasone on a human glioblastoma cell line (HU 197) is mediated by glucocorticoid receptors. (1444223)
1992
46
Analysis of the signals for transcription termination by purified RNA polymerase II. (2157481)
1990
47
Effect of corticosteroid treatment and enucleation on the visual prognosis of sympathetic ophthalmia. (6614106)
1983
48
Intramural duodenal hematoma in children. The role of the radiologist in its conservative management. (1088718)
1976
49
Letter: 5-hydroxytryptamine and hepatic coma. (53461)
1975
50

Variations for Adenosine Deaminase Deficiency

About this section

Clinvar genetic disease variations for Adenosine Deaminase Deficiency:

5
id Gene Variation Type Significance SNP ID Assembly Location
1ADANM_000022.2(ADA): c.890C> A (p.Pro297Gln)single nucleotide variantPathogenicrs121908718GRCh37Chr 20, 43249744: 43249744
2ADANM_000022.2(ADA): c.226C> T (p.Arg76Trp)single nucleotide variantPathogenicrs121908736GRCh37Chr 20, 43255233: 43255233
3ADANM_000022.2(ADA): c.446G> A (p.Arg149Gln)single nucleotide variantPathogenicrs121908737GRCh37Chr 20, 43254242: 43254242
4ADANM_000022.2(ADA): c.821C> T (p.Pro274Leu)single nucleotide variantPathogenicrs121908738GRCh37Chr 20, 43251253: 43251253
5ADANM_000022.2(ADA): c.631C> T (p.Arg211Cys)single nucleotide variantPathogenicrs121908740GRCh37Chr 20, 43251695: 43251695
6ADANM_000022.2(ADA): c.643G> A (p.Ala215Thr)single nucleotide variantPathogenicrs114025668GRCh37Chr 20, 43251683: 43251683
7ADANM_000022.2(ADA): c.454C> A (p.Leu152Met)single nucleotide variantPathogenicrs121908728GRCh37Chr 20, 43254234: 43254234
8ADANM_000022.2(ADA): c.698C> T (p.Thr233Ile)single nucleotide variantPathogenicrs121908729GRCh37Chr 20, 43251552: 43251552
9ADANM_000022.2(ADA): c.467G> A (p.Arg156His)single nucleotide variantPathogenicrs121908722GRCh37Chr 20, 43254221: 43254221

Expression for genes affiliated with Adenosine Deaminase Deficiency

About this section
Search GEO for disease gene expression data for Adenosine Deaminase Deficiency.

Pathways for genes affiliated with Adenosine Deaminase Deficiency

About this section

Pathways related to Adenosine Deaminase Deficiency according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
19.3ADA, IL2RG
2
Show member pathways
9.2ADA, ADK, PNP
3
Show member pathways
8.5ADA, ADK, PNP
4
Show member pathways
8.5ADA, ADK, ITPA, PNP
5
Show member pathways
8.5ADA, ADK, AHCY, ITPA
6
Show member pathways
7.6ADA, ADK, AHCY, GBA, ITPA, PNP

GO Terms for genes affiliated with Adenosine Deaminase Deficiency

About this section

Biological processes related to Adenosine Deaminase Deficiency according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1positive regulation of alpha-beta T cell differentiationGO:004663810.2ADA, PNP
2negative regulation of inflammatory responseGO:00507289.8ADA, GBA
3nucleobase-containing small molecule metabolic processGO:00550869.6ADA, ADK
4response to hypoxiaGO:00016669.6ADA, AHCY
5purine nucleobase metabolic processGO:00061449.5ADK, PNP

Sources for Adenosine Deaminase Deficiency

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet